Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda.

OBJECTIVE To determine the proportion of recurrent tuberculosis (TB) due to relapse with the patient's initial strain or reinfection with a new strain of Mycobacterium tuberculosis 1-2 years after anti-tuberculosis treatment in Uganda, a sub-Saharan TB-endemic country. DESIGN Records of patients with culture-confirmed TB who completed treatment at an urban Ugandan clinic were reviewed. Restriction fragment length polymorphism (RFLP) patterns were used to determine relapse or reinfection. Associations between human immunodeficiency virus (HIV) positivity and type of TB recurrence were determined. RESULTS Of 1701 patients cured of their initial TB episode with a median follow-up of 1.24 years, 171 (10%) had TB recurrence (8.4 per 100 person-years). Rate and risk factors for recurrence were similar to other studies from sub-Saharan Africa. Insertion sequence (IS) 6110-based RFLP of paired isolates from 98 recurrences identified 80 relapses and 18 reinfections. Relapses among HIV-positive and -negative patients were respectively 79% and 85% of recurrences. CONCLUSIONS Relapse was more common and presented earlier than reinfection in both HIV-positive and -negative TB patients 1-2 years after completing treatment. These findings impact both the choice of retreatment drug regimen, as relapsing patients are at higher risk for acquired drug resistance, and clinical trials of new TB regimens with relapse as clinical endpoint.

[1]  R. Prescott,et al.  Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. , 1991, Respiratory medicine.

[2]  J. T. Crawford,et al.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology , 1993, Journal of clinical microbiology.

[3]  J. Paul,et al.  Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  C. Martín,et al.  Use of a PCR method based on IS6110 polymorphism for typing Mycobacterium tuberculosis strains from BACTEC cultures , 1997, Journal of clinical microbiology.

[5]  M. Behr,et al.  Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P D van Helden,et al.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. , 1999, The New England journal of medicine.

[7]  J. Ellner,et al.  Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda. , 2000, East African medical journal.

[8]  D. Hom,et al.  Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  John L. Johnson,et al.  Randomized Controlled Trial of Mycobacterium vaccae Immunotherapy in Non-Human Immunodeficiency Virus-Infected Ugandan Adults with Newly Diagnosed Pulmonary Tuberculosis , 2000 .

[10]  P. Sonnenberg,et al.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers , 2001, The Lancet.

[11]  O Afonso,et al.  Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. , 2001, American journal of respiratory and critical care medicine.

[12]  E. Bouza,et al.  Tuberculosis recurrences: reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. , 2002, Archives of internal medicine.

[13]  I. Onorato,et al.  An investigation of suspected exogenous reinfection in tuberculosis patients in Kampala, Uganda. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  John L. Johnson,et al.  Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[15]  D. Guwatudde,et al.  Burden of tuberculosis in Kampala, Uganda. , 2003, Bulletin of the World Health Organization.

[16]  B. Metchock,et al.  Recurrent tuberculosis in the United States and Canada: relapse or reinfection? , 2004, American journal of respiratory and critical care medicine.

[17]  S. Ho,et al.  A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[18]  Donald A Enarson,et al.  Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[19]  J. Ellner,et al.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. , 2005, The Journal of infectious diseases.

[20]  W. Boom,et al.  Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. , 2006, The American journal of tropical medicine and hygiene.

[21]  J. Ellner,et al.  Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  J. Golub,et al.  Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  Pan‐Chyr Yang,et al.  Prediction of the tuberculosis reinfection proportion from the local incidence. , 2007, The Journal of infectious diseases.

[24]  R. Chaisson,et al.  Contribution of reinfection to recurrent tuberculosis in South African gold miners. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  G. Marks,et al.  Recurrence of tuberculosis at a Sydney chest clinic between 1994 and 2006: reactivation or reinfection? , 2008, The Medical journal of Australia.

[26]  John L. Johnson,et al.  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. , 2009, American journal of respiratory and critical care medicine.

[27]  M. Joloba,et al.  Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda , 2010, BMC infectious diseases.

[28]  D. Mitchison,et al.  Timing of relapse in short-course chemotherapy trials for tuberculosis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  A. Crampin,et al.  Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi , 2010, AIDS.

[30]  D. Havlir,et al.  A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL. , 2011, The Journal of infectious diseases.